Skip to main content
SpringerLink
Log in

Zollinger-Ellison Syndrome

Recognition and Management of Acid Hypersecretion

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Zollinger-Ellison syndrome (ZES) should be suspected if a patient has severe peptic ulceration, ulcers and kidney stones, a family history of ulcers or endocrine diseases, watery diarrhoea or malabsorption with or without ulcers, or if hyper-gastrinaemia is found. Any patient in whom ZES is suspected, and certainly if diagnosed, should be given large doses of antisecretory medication immediately. This should never be stopped except under controlled conditions or unless acid outputs have been reduced surgically. Patients cannot be managed safely without measuring acid outputs. These should be lowered to < 10 mmol/h, or <5 mmol/h in patients with a previous gastric resection or severe oesophageal disease. Acid secretion can be controlled acutely in 70% of patients with an infusion of ranitidine 1 mg/kg/h, while 4 mg/kg/h will control acid in all. The initial oral dosage of omeprazole or lansoprazole should be 60 mg/day. Doses should then be adjusted daily on the basis of acid outputs. Proton pump inhibitors in a dosage of 60 mg/day will control acid output in most patients and 60mg every 12 hours will control acid output in all. Doses can then often be slowly and progressively reduced. A parietal cell vagotomy reduces acid secretion and reduces, but does not abolish, the need for antisecretory medication. In patients with multiple endocrine neoplasia type 1 and hyperparathyroidism, a parathyroidectomy that results in normocalcaemia will reduce acid secretion and drug requirements. A total gastrectomy is rarely if ever needed nowadays.

Given the high degree of safety of gastric antisecretory medications versus the risks of acid hypersecretion in patients with ZES, the mistakes in management of acid hypersecretion that must be avoided are those of giving insufficient medication and not measuring acid secretory rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: reap-praisal and evaluation of 260 registered cases. Ann Surg 1964; 160: 512–53

    Article  PubMed  CAS  Google Scholar 

  2. Fox PS, Hofman JW, Wilson SD, et al. Surgical management of Zollinger-Ellison syndrome. Surg Clin North Am 1974; 54: 395–407

    PubMed  CAS  Google Scholar 

  3. Thompson JC, Lewis BG, Wiener I, et al. The role of surgery in the Zollinger-Ellison syndrome. Ann Surg 1983; 197: 594–607

    Article  PubMed  CAS  Google Scholar 

  4. Buchanan KD, Johnston CF, O’Hare MMT, et al. Neuroendocrine tumors: a European view. Am J Med 1986; 81 Suppl.68: 14–23

    Article  PubMed  CAS  Google Scholar 

  5. Vinayek R, Frucht H, Chiang H-CV, et al. Zollinger-Ellison syndrome: recent advances in the management of the gastrinoma. Gastroenterol Clin North Am 1990; 19: 197–218

    PubMed  CAS  Google Scholar 

  6. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: advances in the treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271: 1429–35

    Article  PubMed  CAS  Google Scholar 

  7. Maton PN. The management of Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993; 7: 467–75

    Article  PubMed  CAS  Google Scholar 

  8. Jensen RT, Gardner JD, Gastrinoma. In: Go VLW, Brooks FP, DiMagno EP, et al., editors. The pancreas: biology, pathobiology and diseases, 2nd ed. New York: Raven Press, 1993: 931–78

    Google Scholar 

  9. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. N Engl J Med 1987; 317: 1200–9

    Article  PubMed  CAS  Google Scholar 

  10. Eberle F, Grun R. Multiple endocrine neoplasia, type I (MENI). Ergeb Inn Med Kinderheilkd 1981; 46: 75–150

    Google Scholar 

  11. Bale AE, Norton JA, Wong EL, et al. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res 1991; 51: 1154–7

    PubMed  CAS  Google Scholar 

  12. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983; 84: 108–13

    PubMed  CAS  Google Scholar 

  13. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36: 394–404

    Article  PubMed  CAS  Google Scholar 

  14. Jensen RT, Gardner JD, Raufman JP, et al. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983; 98: 59–75

    PubMed  CAS  Google Scholar 

  15. Maton PN, Gardner JD, Jensen RT. Recent advances in the management of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterol Clin North Am 1989; 18: 847–64

    PubMed  CAS  Google Scholar 

  16. Vinayek R, Howard JM, Maton PN, et al. Famotidine in the therapy of gastric hypersecretory states. Am J Med 1983; 81 Suppl.4B: 49–59

    Google Scholar 

  17. Saeed ZA, Norton JA, Frank WO, et al. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 1989; 96: 1393–402

    PubMed  CAS  Google Scholar 

  18. Fraker D, Norton JA, Saeed ZA, et al. A prospective study of pre-and post-operative control of acid hypersecretion in patients with Zollinger-Ellison syndrome. Surgery 1988; 104: 1054–63

    PubMed  CAS  Google Scholar 

  19. Vinayek R, Frucht H, London JF, et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990; 99: 10–6

    PubMed  CAS  Google Scholar 

  20. Romeo DP, Weesner RE, Giannella RA. Misdiagnosis of the Zollinger-Ellison syndrome due to hyperlipidemia. Gastroenterology 1990; 99: 1511–3

    PubMed  CAS  Google Scholar 

  21. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 1989; 111: 713–22

    PubMed  CAS  Google Scholar 

  22. Goldschmiedt M, Feldman M. Gastric secretion in health and disease. In: Sleisenger MM, Fordtran JS, editors. Gastrointestinal disease, 5th ed. Philadelphia: Saunders, 1983: 524–44

    Google Scholar 

  23. Korman MG, Scott DF, Hansby J. Hypergastrinemia due to extended gastric antrum: a proposed method for differentiation from Zollinger-Ellison syndrome. Aust NZ J Med 1972; 3: 266–71

    Article  Google Scholar 

  24. Feurle G, Ketterer H, Becker HD, et al. Circadian serum gastrin concentrations in control persons and in patients with ulcer disease. Scand J Gastroenterol 1972; 7: 177–83

    PubMed  CAS  Google Scholar 

  25. Lewin KJ, Yang K, Ulrich T, et al. Primary gastrin hyperplasia: report of five cases and a review of the literature. Am J Surg Pathol 1984; 8: 821–32

    Article  PubMed  CAS  Google Scholar 

  26. Graham DY, Opekun A, Lew GM, et al. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol 1990; 85: 394–8

    PubMed  CAS  Google Scholar 

  27. Annibale De Magitris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G cell hyperfunction in patients with resistant ulcer disease. Aliment Pharmacol Ther 1994; 8: 87–93

    Article  Google Scholar 

  28. Maton PN. Role of acid suppressants in patients with Zollinger- Ellison syndrome. Aliment Pharmacol Ther 1991; 5 Suppl.1: 25–36

    PubMed  Google Scholar 

  29. Maton PN. Omeprazole. N Engl J Med 1991; 324: 965–75

    Article  PubMed  CAS  Google Scholar 

  30. McArthur KE, Collen MJ, Maton PN, et al. Omeprazole: effective convenient therapy for Zollinger-Ellison syndrome. A prospective study. Gastroenterology 1989; 97: 827–36

    PubMed  Google Scholar 

  31. Lamers CBHW, Lind T, Moberg S, et al. Omeprazole in Zollinger-Ellison syndrome: effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med 1984; 310: 758–76

    Article  Google Scholar 

  32. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in Zollinger-Ellison syndrome: four year international study. Aliment Pharmacol Ther 1988; 2: 13–37

    Article  PubMed  CAS  Google Scholar 

  33. Delchier JC, Soule JC, Mignon M, et al. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Dig Dis Sci 1986; 31: 693–9

    Article  PubMed  CAS  Google Scholar 

  34. Metz D, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 245–56

    Article  PubMed  CAS  Google Scholar 

  35. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: a prospective 9 year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597–610

    Article  PubMed  CAS  Google Scholar 

  36. Mignon M, Hochlaf S, Forestier S, et al. Effet dose-response du lansoprazole chez des malades atteints d’un syndrome de Zollinger-Ellison. Gastroenterol Clin Biol 1994; 18: 13–6

    Article  PubMed  CAS  Google Scholar 

  37. Hirschowitz BJ, Mohnen J, Shaw S. Zollinger-Ellison syndrome treated with lansoprazole [abstract]. Gastroenterology 1993; 104: A100

    Google Scholar 

  38. Wilde M, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid related disorders. Drugs 1994; 48: 91–132

    Article  PubMed  CAS  Google Scholar 

  39. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404–30

    Article  PubMed  CAS  Google Scholar 

  40. Corleto V, Annibale B, D’Ambra G, et al. Efficacy of long term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. Aliment Pharmacol Ther 1993; 7: 167–74

    Article  PubMed  CAS  Google Scholar 

  41. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498–1508

    PubMed  CAS  Google Scholar 

  42. Jensen RT, Metz DC, Koviak PD, et al. Prospective study of the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993; 7 Suppl.1: 41–50

    PubMed  Google Scholar 

  43. Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg M, editors. Peptic ulcer disease and other acid related disorders. Armonk (NY): Academic Research Associates, 1991: 213–46

    Google Scholar 

  44. Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia: a newly recognized association. Am J Surg Path 1990; 14: 503–13

    Article  PubMed  CAS  Google Scholar 

  45. Rindi G, Luinetti I, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994–1006

    PubMed  CAS  Google Scholar 

  46. Maton PN, Lack Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric endocrine cells. Gastroenterology 1990; 99: 943–50

    PubMed  CAS  Google Scholar 

  47. Lehy T, Mignon M, Cadiot G, et al. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long term potent antisecretory treatment. Gastroenterology 1989; 96: 1029–40

    PubMed  CAS  Google Scholar 

  48. Howard JM, Chremos AN, Collen MJ, et al. Famotidine, a new potent long acting histamine H2 receptor antagonist: comparison with cimetidine and ranitidine in patients with Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 1026–33

    PubMed  CAS  Google Scholar 

  49. McCarthy DM, Hyman PE. Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1982; 27: 353–9

    Article  PubMed  CAS  Google Scholar 

  50. Maton PN. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am 1989; 18: 897–922

    PubMed  CAS  Google Scholar 

  51. Annibale B, Delle Fave G, Azzoni C et al. Three months of octreotide treatment decreases acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G cell hyperfunction. Aliment Pharmacol Ther 1994; 8: 95–104

    Article  PubMed  CAS  Google Scholar 

  52. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294–9

    PubMed  CAS  Google Scholar 

  53. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341–6

    Article  PubMed  CAS  Google Scholar 

  54. Metz DC, Benya RV, Fishbeyn VA, et al. Prospective study of the need for long term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther 1993; 7: 247–57

    Article  PubMed  CAS  Google Scholar 

  55. Pisegna J, Norton J, Slimak G, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767–78

    PubMed  CAS  Google Scholar 

  56. Norton J, Doppman J, Jensen R. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 1992; 215: 8–18

    Article  PubMed  CAS  Google Scholar 

  57. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism and Zollinger-Ellison syndrome and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102: 958–66

    PubMed  CAS  Google Scholar 

  58. Richardson CT, Peters MN, Feldman M, et al. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists: a prospective study. Gastroenterology 1985; 89: 357–67

    PubMed  CAS  Google Scholar 

  59. McArthur K, Richardson C, Eshagi N, et al. Prospective trial of exploratory laparotomy (LAP) and proximal gastric vagotomy (PGV) for Zollinger-Ellison syndrome (ZES). Long term follow up (F/U) [abstract]. Gastroenterology 1993; 104: A144

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oklahoma Foundation for Digestive Research, 711 Stanton L. Young Boulevard, Suite 501, Oklahoma City, Oklahoma, 73104, USA

    Paul N. Maton

Authors
  1. Paul N. Maton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maton, P.N. Zollinger-Ellison Syndrome. Drugs 52, 33–44 (1996). https://doi.org/10.2165/00003495-199652010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652010-00003

Keywords

Search

Navigation